Related Experiment Video
Updated: May 13, 2025

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Impact of milbemycin oxime on fluconazole resistance in Candida auris
Lola Aubry1, Danielle Brandalise1, Marine Louvet1
1Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Background:
Candida auris is a pathogenic yeast that can develop resistance to multiple antifungals, particularly to azoles (e.g. fluconazole). Milbemycin oxime potentiates the effect of fluconazole against Candida spp. by inhibiting ABC transporters, such as Cdr1, which is involved in azole drug efflux.
Objectives:
This study aimed to assess the interaction of milbemycin oxime and fluconazole against clinical (n = 4) and laboratory-generated (n = 4) C. auris isolates with different mechanisms of azole resistance.
Methods:
Interactions of milbemycin oxime and fluconazole were assessed by chequerboard assays and defined as synergistic, indifferent or antagonistic according to the FIC index (FICI) values. The fluorescent substrate rhodamine 6 g (R6G) was used to measure ABC transporter activity in the absence or presence of milbemycin oxime.
Results:
A synergistic interaction between milbemycin oxime and fluconazole was observed against most isolates, including those harbouring Cdr1-independent mechanisms of azole resistance (e.g. ERG11 mutations). The highest synergism was observed in a laboratory-generated strain overexpressing CDR1, while the interaction was indifferent in a strain lacking CDR1. R6G experiments confirmed the inhibitory effect of milbemycin oxime on ABC transporters.
Conclusions:
Milbemycin oxime could represent an interesting adjunctive therapy against azole-resistant C. auris, particularly those with CDR1 overexpression.
Insights
Milbemycin oxime enhances fluconazole
Area of Science:
- Mycology and Antimicrobial Resistance
Background:
- Candida auris is a multidrug-resistant yeast, particularly to azole antifungals like fluconazole.
- Azole resistance in C. auris is often mediated by efflux pumps, such as Cdr1.
- Milbemycin oxime inhibits ABC transporters, potentially reversing azole resistance.
Purpose of the Study:
- To evaluate the combined effect of milbemycin oxime and fluconazole against Candida auris.
- To investigate the interaction in clinical and laboratory-generated C. auris isolates with diverse azole resistance mechanisms.
Main Methods:
- Chequerboard assays were used to determine the fractional inhibitory concentration index (FICI) for drug interactions.
- Activity of ABC transporters was measured using rhodamine 6g (R6G) fluorescence.
- Experiments included clinical and laboratory-derived C. auris strains with known resistance mechanisms.
Main Results:
- A synergistic interaction between milbemycin oxime and fluconazole was observed against most C. auris isolates.
- Synergism was noted even in isolates with Cdr1-independent azole resistance mechanisms (e.g., ERG11 mutations).
- Milbemycin oxime demonstrated inhibition of ABC transporters, confirmed by R6G experiments.
Conclusions:
- Milbemycin oxime shows potential as an adjunctive therapy to overcome azole resistance in Candida auris.
- The combination is particularly promising for C. auris strains exhibiting high CDR1 overexpression.
Related Concept Videos
Genomic DNA in Prokaryotes
Genomic Diversity in Bacteria
Although bacterial genomes are much...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

